Provided by Tiger Trade Technology Pte. Ltd.

Aurinia Pharmaceuticals

16.65
-0.6200-3.59%
Post-market: 16.650.00000.00%19:31 EDT
Volume:1.25M
Turnover:21.02M
Market Cap:2.22B
PE:7.23
High:17.32
Open:17.20
Low:16.63
Close:17.27
52wk High:19.25
52wk Low:10.34
Shares:133.05M
Float Shares:129.00M
Volume Ratio:0.91
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.30
EPS(LYR):2.07
ROE:66.12%
ROA:15.49%
PB:3.60
PE(LYR):8.04

Loading ...

Aurinia Pharmaceuticals Inc - CVR Includes Payments From Zetomipzomib, Everest, Enodia, and Net Cash Over $50 Mln

THOMSON REUTERS
·
Mar 30

How Aurinia’s Tang-Led C-Suite Overhaul Will Impact Aurinia Pharmaceuticals (AUPH) Investors

Simply Wall St.
·
Mar 30

MKT Capital ‘applauds’ Aurinia’s management transition

TIPRANKS
·
Mar 23

Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning

Benzinga_recent_news
·
Mar 23

BRIEF-Aurinia Announces Management Transition

Reuters
·
Mar 23

Aurinia names Kevin Tang CEO, appoints Ryan Cole COO

Reuters
·
Mar 23

Aurinia Pharmaceuticals Inc - Appoints Kevin Tang as CEO Succeeding Peter Greenleaf

THOMSON REUTERS
·
Mar 23

Aurinia Pharmaceuticals Inc - Appoints Michael Hearne as CFO

THOMSON REUTERS
·
Mar 23

13D Filings -- Barrons.com

Dow Jones
·
Mar 14

The Bull Case For Aurinia Pharmaceuticals (AUPH) Could Change Following Strong 2025 Results And Upbeat 2026 Outlook

Simply Wall St.
·
Mar 09

Angkor Resources Closes $4.8M Sale of Evesham Oil and Gas Assets

Reuters
·
Mar 06

Aurinia Pharmaceuticals Earnings Call Highlights Growth And Risks

TIPRANKS
·
Mar 06

Aurinia Pharmaceuticals Director Kevin Tang Reports Acquisition of Common Shares

Reuters
·
Mar 04

Assessing Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Swings

Simply Wall St.
·
Mar 04

Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)

TIPRANKS
·
Mar 02

RBC Capital Remains a Hold on Aurinia Pharmaceuticals (AUPH)

TIPRANKS
·
Feb 27

Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets

Benzinga Earnings
·
Feb 27

Stock Track | Aurinia Pharmaceuticals Plummets 5.13% Intraday as 2026 Revenue Guidance Misses Estimates

Stock Track
·
Feb 27

UPDATE: Aurinia Pharmaceuticals Q4 Adj. EPS $0.26 Beats $0.22 Estimate

Benzinga Earnings
·
Feb 26

Stock Track | Aurinia Pharmaceuticals Soars 5.20% in Pre-market on Strong Q4 Earnings Beat and Robust Guidance

Stock Track
·
Feb 26